France's Sanofi-Aventis has agreed to acquire San Diego-based TargeGen, a biopharmaceutical company, for up to $560 million. Sanofi-Aventis will make an upfront payment of $75 million upon closing of the deal, which is expected in the third quarter. Further milestones payments will occur at different stages of development of TargeGenÔÇÖs lead product TG 101348. TargeGen develops kinase inhibitors for the treatment of leukemia, lymphona and other blood disorders.